|
|
|
| Effects of Geniposide on Gefitinib Resistance in Non-Small Cell Lung Cancer Cells by Regulating Akt/MDM2/p53 Signaling Pathway |
| QIAN Xia, NI Feng, TAN Cheng, et al |
| Nantong University Affiliated Cancer Hospital, Jiangsu Nantong 226000, China |
|
|
|
|
Abstract Objective: To explore whether geniposide (GEN) can reduce gefitinib resistance in non-small cell lung cancer (NSCLC) cells by regulating the Akt/MDM2/p53 signaling pathway. Methods: Human NSCLC cell lines PC9 sensitive to gefitinib and PC9/GR resistant to gefitinib were cultured in vitro. PC9/GR cells with good growth status were stochastically assigned into Control group, L-GEN, M-GEN, H-GEN groups (5, 10, 20mg/mL GEN), and H-GEN+SC79 group (20mg/mL GEN+8μg/mL Akt activator SC79). CCK8 method was performed to detect cell proliferation. The plate cloning experiment was used to detect the ability of cells to form clones. Flow cytometry was performed to detect cell apoptosis. Transwell experiment was performed to detect cell invasion. Western blot was used to detect MDR1, MMP-2, MMP-9, and Akt/MDM2/p53 signaling pathway proteins. Results: The L-GEN group, M-GEN group, and H-GEN group had lower OD450 values of PC9/GR cells, colony formation rates, cell invasion counts, MDR1, MMP-2, MMP-9, and p-Akt/Akt, p-MDM2/MDM2 protein expression compared to the Control group, while apoptosis rates and p53 protein expression were higher (P<0.05); the H-GEN+SC79 group showed higher OD450 values, colony formation rates, cell invasion counts, MDR1, MMP-2, MMP-9, p-Akt/Akt, p-MDM2/MDM2 protein expression and lower apoptosis rates and p53 protein expression compared to the H-GEN group (P<0.05). Conclusion: GEN primarily weakens the resistance of NSCLC cells to gefitinib by inhibiting the Akt/MDM2/p53 pathway.
|
|
|
|
|
|
[1] Tan AC.Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)[J].Thorac Cancer,2020,11(3):511-518.
[2] Luan L,Wang H,Zhao B,et al.Association of MDM2 gene SNP 309 polymorphism and human non-small cell lung cancer susceptibility:a meta-analysis[J].Pathol Res Pract,2019,215(9):152-163.
[3] Bi YY,Chen Q,Yang MY,et al.Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer[J].Nat Commun,2024,15(1):275-293.
[4] Zhang J,Li C,Li W,et al.Mechanism of luteolin against non-small-cell lung cancer:a study based on network pharmacology,molecular docking,molecular dynamics simulation,and in vitro experiments[J].Front Oncol,2024,12(3):105-119.
[5] 娄静,赵雷,朱岩洁,等.扶正软坚抗癌方调控Akt/MDM2/P53信号通路对肝癌HepG2细胞恶性生物学行为的影响[J].吉林大学学报(医学版),2024,50(6):1654-1663.
[6] Zhang C,Wang N,Tan HY,et al.Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma[J].Br Pharmacol,2020,177(14):3240-3257.
[7] Lv K,Zhu J,Zheng S,et al.Evaluation of inhibitory effects of geniposide on a tumor model of human breast cancer based on 3D printed Cs/Gel hybrid scaffold[J].Mater Sci Eng C Mater Biol Appl,2021,13(5):119-128.
[8] Chen R,Herrera AF,Hou J,et al.Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma[J].Clin Cancer Res,2020,26(5):1034-1044.
[9] Sun D,Liu J,Wang Y,et al.Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma[J].Front Oncol,2022,14(3):12-26.
[10] Liao XZ,Gao Y,Sun LL,et al.Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway[J].Phytother Res,2020,34(5):1142-1153.
[11] Wei C,Du J,Shen Y,et al.Anticancer effect of involucrasin A on colorectal cancer cells by modulating the Akt/MDM2/p53 pathway[J].Oncol Lett,2023,25(6):218-226.
[12] Zhao Y,Cai J,Shi K,et al.Germacrone induces lung cancer cell apoptosis and cell cycle arrest via the Akt/MDM2/p53 signaling pathway[J].Mol Med Rep,2021,23(6):452-460. |
|
|
|
2025, Vol. 31 
